BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23681900)

  • 1. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
    Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
    Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
    Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Denisov EV; Garbukov EY; Merzliakova MK; Volkomorov VV; Vtorushin SV; Zavyalova MV; Slonimskaya EM; Perelmuter VM
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):153-63. PubMed ID: 23053273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells.
    Xu JW; Li QQ; Tao LL; Cheng YY; Yu J; Chen Q; Liu XP; Xu ZD
    Int J Oncol; 2011 Dec; 39(6):1501-9. PubMed ID: 21805028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
    Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
    Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
    McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
    Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer.
    Loh TJ; Moon H; Cho S; Jang H; Liu YC; Tai H; Jung DW; Williams DR; Kim HR; Shin MG; Liao DJ; Zhou J; Shi W; Zheng X; Shen H
    Oncol Rep; 2015 Sep; 34(3):1231-8. PubMed ID: 26151392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of angio-associated migratory cell protein (AAMP) on breast cancer cells in vitro and its clinical significance.
    Yin Y; Sanders AJ; Jiang WG
    Anticancer Res; 2013 Apr; 33(4):1499-509. PubMed ID: 23564791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.